Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$132.43 USD

132.43
4,690,585

+0.37 (0.28%)

Updated Aug 8, 2025 09:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

NuVasive (NUVA), ISSGF Expand Tie-Up With Launch of 2 Studies

by Zacks Equity Research

NuVasive (NUVA) extends its long-term partnership with ISSGF and initiates additional clinical studies to transform the future of spine care.

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings, Revenues Beat Estimates

by Zacks Equity Research

HealthEquity (HQY) delivers solid growth in HSAs and custodial assets in the fiscal fourth quarter.

Zacks Equity Research

Why You Should Add Surmodics (SRDX) to Your Portfolio Now

by Zacks Equity Research

Investor optimism is high on Surmodics (SRDX) stock, courtesy of its solid prospects.

Zacks Equity Research

Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine

by Zacks Equity Research

Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.

Zacks Equity Research

Here's Why You Should Retain Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.

Zacks Equity Research

Quest Diagnostics (DGX) Inks Agreement to Enhance Cardiac Care

by Zacks Equity Research

Quest Diagnostics (DGX) signs agreement with Zora to develop cardiovascular mortality prediction test with the help of the latter's patented ceramide-analysis technology.

Zacks Equity Research

Luminex (LMNX) Files EUA Application for New Respiratory Assay

by Zacks Equity Research

Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.

Zacks Equity Research

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Allscripts (MDRX) stock, courtesy of solid prospects.

Zacks Equity Research

Cardinal Health (CAH) Inks Deal to Divest Cordis Business

by Zacks Equity Research

Cardinal Health (CAH) divests its Cordis business to focus on strategic growth areas.

Zacks Equity Research

Here's Why You Should Retain AmerisourceBergen (ABC) Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.

Zacks Equity Research

Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ABT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Here's Why You Should Add McKesson (MCK) to Your Portfolio Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

Zacks Equity Research

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $117.52, moving +1.42% from the previous trading session.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.

Zacks Equity Research

PerkinElmer (PKI) Boosts Testing Portfolio With New Solutions

by Zacks Equity Research

PerkinElmer's (PKI) introduction of two comprehensive solutions is likely to strengthen its COVID-19 testing portfolio further.

Zacks Equity Research

BD (BDX), ImageMover Partner for Rapid Antigen Test Reporting

by Zacks Equity Research

BD (BDX) collaborates with ImageMover to streamline rapid antigen testing results performed on the BD Veritor Plus System.

Zacks Equity Research

Intersect ENT (XENT) Q4 Loss Wider Than Expected, Revenues Top

by Zacks Equity Research

Intersect ENT's (XENT) sequentially rebound is strong on continued recovery in PROPEL, growth in SINUVA and initial sales of the company???s newly acquired Fiagon products.

Zacks Equity Research

Here's Why You Should Retain AMN Healthcare (AMN) Stock Now

by Zacks Equity Research

Investor optimism is high on AMN Healthcare (AMN) stock, courtesy of its solid prospects.

Zacks Equity Research

Abbott (ABT) Launches Telehealth Tool for Neuromodulation

by Zacks Equity Research

Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.

Zacks Equity Research

BD (BDX) Acquires GSL Solutions for Medication Management

by Zacks Equity Research

This acquisition should improve BD's (BDX) advanced medication management capabilities to further cater to the needs of retail pharmacies including those in outpatient settings.

Zacks Equity Research

Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now

by Zacks Equity Research

Investor optimism is high on NextGen (NXGN) stock, courtesy of its solid prospects.

Zacks Equity Research

Abbott's (ABT) Diagnostics Arm to Gain From New & Updated EUAs

by Zacks Equity Research

Abbott's (ABT) Alinity m SARS-CoV-2 test set to detect COVID-19 in individuals who do not have symptoms.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic

Zacks Equity Research

Abbott (ABT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $117.25, marking a +1.07% move from the previous day.

Zacks Equity Research

Cooper Companies (COO) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.